Skip to Content

Smith & Nephew PLC

SN.: XLON (GBR)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 5,445.00JpmqsSqxfxvwwx

Smith & Nephew Stuck in Midtier Competitive Position; No Change to Our Fair Value Estimate

While we generally applaud narrow-moat Smith & Nephew’s recent strategic decisions and operational efforts, we’re still not highly confident that this midsize competitor will be able to thrive in a market that has become more and more highly consolidated, especially as hospital customers have sought to leverage volume purchases with fewer vendors. We’ve seen little in recent results to shift our intrinsic value, though we’re mindful that increasing transmission of the delta variant could put pressure on the resumption of elective procedure volume in localized geographies as we head into the fall. If this comes to pass, it would knock roughly $1 off our $43 fair value estimate.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SN. so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center